cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Protagonist Therapeutics Inc
15 own
13 watching
Current Price
$26.25
$0.89
(3.51%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,350.31M
52-Week High
52-Week High
26.87
52-Week Low
52-Week Low
6.91
Average Volume
Average Volume
0.85M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,350.31M
icon52-Week High26.87
icon52-Week Low6.91
iconAverage Volume0.85M
iconDividend Yield--
iconP/E Ratio--
What does the Protagonist Therapeutics Inc do?
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Read More
How much money does Protagonist Therapeutics Inc make?
News & Events about Protagonist Therapeutics Inc.
Accesswire
1month ago
NEWARK, CA / ACCESSWIRE / April 4, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ('Protagonist' or the 'Company') today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per...
PR Newswire
7 months ago
Thinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro? Thinking about buying stock in Protagonist Therapeutics, BP, Nio, Axsome Therapeutics, or Petroleo Brasileiro? PR Newswire NEW YORK, Oct. 3, 2022 NEW YORK, Oct. 3, 2022 /PRNewswire...
Ticker Report
1 year ago
Protagonist Therapeutics (NASDAQ:PTGX Get Rating) was downgraded by StockNews.com from a hold rating to a sell rating in a note issued to investors on Friday. Several other equities analysts have also recently issued reports on the company. Piper Sandler decreased...
Zolmax
1 year ago
Protagonist Therapeutics (NASDAQ:PTGX Get Rating) was downgraded by StockNews.com from a hold rating to a sell rating in a note issued to investors on Friday. Several other equities analysts have also recently issued reports on the company. Piper Sandler decreased their price objective on ...
Ticker Report
1 year ago
Northern Trust Corp lessened its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX Get Rating) by 0.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 455,411 shares of the company&#...
Frequently Asked Questions
Frequently Asked Questions
What is Protagonist Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Protagonist Therapeutics Inc shares?
plus_minus_icon
How can I buy Protagonist Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Protagonist Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Protagonist Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Protagonist Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Protagonist Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Protagonist Therapeutics Inc?
plus_minus_icon
What percentage is Protagonist Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Protagonist Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$26.25
$0.89
(3.51%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
CHINOOK THERAPEUTICS INC
CHINOOK THERAPEUTICS INC
$23.31
$1.75 (8.12 %)
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$22.10
$0.13 (0.59 %)
89bio Inc
89bio Inc
$17.69
$1.14 (6.89 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$22.03
$4.53 (25.89 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
CHINOOK THERAPEUTICS INC
CHINOOK THERAPEUTICS INC
$23.31
$1.75 (8.12 %)
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$22.10
$0.13 (0.59 %)
89bio Inc
89bio Inc
$17.69
$1.14 (6.89 %)
Arcus Biosciences Inc
Arcus Biosciences Inc
$22.03
$4.53 (25.89 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00